A miRNA-Based Signature Detected in Primary Melanoma Tissue Predicts Development of Brain Metastasis

Abstract

A prognostic assay based on the described miRNA expression signature combined with the currently used staging criteria may improve accuracy of primary melanoma patient prognoses and aid clinical management of patients, including selection for adjuvant treatment or clinical trials of adjuvant therapies.